Top Page
Healios KK
(4593)
Healios KK (4593) vs. iShares MSCI Japan ETF (EWJ)
Healios KK Business Overview & Revenue Model
Healios KK Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 97.00M | 560.00M | 121.00M | 90.00M | 41.00M | 27.00M |
| Gross Profit | -278.00M | 432.00M | 108.00M | 90.00M | 41.00M | 27.00M |
| EBITDA | -1.09B | -2.54B | -3.16B | -4.52B | -3.61B | -3.97B |
| Net Income | -3.89B | -4.24B | -3.82B | -5.17B | -4.91B | -5.51B |
Balance Sheet | ||||||
| Total Assets | 17.33B | 14.19B | 15.15B | 15.03B | 23.97B | 23.17B |
| Cash, Cash Equivalents and Short-Term Investments | 6.50B | 3.67B | 6.72B | 7.25B | 15.13B | 13.92B |
| Total Debt | 2.63B | 2.66B | 4.53B | 7.15B | 11.96B | 11.40B |
| Total Liabilities | 14.37B | 12.11B | 11.29B | 10.65B | 15.33B | 15.32B |
| Stockholders Equity | 2.94B | 2.06B | 3.86B | 4.38B | 8.64B | 7.84B |
Cash Flow | ||||||
| Free Cash Flow | -2.98B | -1.83B | -2.85B | -4.86B | -5.39B | -4.26B |
| Operating Cash Flow | -2.90B | -1.82B | -2.82B | -4.60B | -5.09B | -3.94B |
| Investing Cash Flow | -1.59B | -1.42B | -1.12B | -909.00M | -736.00M | -1.22B |
| Financing Cash Flow | 6.41B | 77.00M | 3.34B | -2.50B | 6.99B | 803.00M |
Healios KK Technical Analysis
Healios KK Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | ¥15.07B | -54.05 | ― | ― | 1.24% | -33.41% | |
57 Neutral | ¥21.93B | -47.52 | ― | ― | -5.65% | -469.19% | |
55 Neutral | ¥65.25B | -97.23 | ― | ― | 1772.85% | 16.16% | |
52 Neutral | ¥11.60B | -10.60 | ― | ― | -42.49% | -2.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | ¥44.21B | -9.72 | ― | ― | -82.33% | 47.73% | |
43 Neutral | ¥18.18B | -9.50 | ― | ― | ― | 11.34% |
Healios KK Corporate Events
Healios K.K. has signed a letter of intent with Japanese pharmaceutical wholesaler Alfresa Corporation to establish a framework for the continuous sale and purchase of its human bone marrow-derived somatic stem cell culture supernatant, HLSI071. Building on an existing business alliance covering distribution and sales, the agreement is intended to secure stable, efficient nationwide distribution of the culture supernatant via Alfresa’s extensive network, enhancing timely delivery to customers. With the launch of its own manufacturing facility for culture supernatant, Healios will end earlier discussions on a potential manufacturing alliance with Alfresa group company Cell Resources, signaling a shift to in-house production while leveraging Alfresa for market access. The company stated that the arrangement is not expected to affect its consolidated financial results for the current fiscal year, but it strengthens its commercialization infrastructure in Japan’s regenerative medicine market.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen301.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
Healios K.K. has submitted a clinical trial plan notification to Japan’s Pharmaceuticals and Medical Devices Agency to begin domestic participation in the pivotal global Phase 3 REVIVE-ARDS study of its stem cell therapy HLCM051 (invimestrocel) for pneumonia-induced acute respiratory distress syndrome, with Japanese patient enrollment expected to start following a 14-day review period before expanding in parallel to other regions including the US, Asia-Pacific and Europe. The trial, designed as a randomized, placebo-controlled study of up to 550 patients with interim analyses and ventilator-free days as the primary endpoint, will serve as a key confirmatory study supporting the company’s strategy to seek conditional and time-limited approval for ARDS in Japan based on positive Phase 2 results, marking a significant step in advancing a potential first-in-class therapy in an area with no approved drugs that directly improve prognosis, though the company expects no immediate impact on its 2026 financial guidance.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen301.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
Healios K.K. disclosed that a lawsuit has been filed against the company by AND medical group in the Tokyo District Court, alleging default and incomplete performance under a joint research agreement signed in April 2024 concerning the use of Healios technology and culture supernatant. AND medical group is seeking ¥120 million in damages plus litigation costs, but Healios maintains that it has properly fulfilled its contractual obligations, considers the claims entirely without merit, and intends to defend its position in court while continuing discussions with multiple partners for culture supernatant sales, stating that its current business policy remains unchanged.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen286.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
Healios K.K. has announced changes in its management and organizational structure, effective January 1, 2026. Notably, Yoshie Tsurumaki will become an Executive Officer, leveraging her extensive experience in cell therapy and oncology to lead the newly established Medical Affairs Division. This strategic move is expected to enhance the company’s engagement with healthcare professionals and improve the medical value of its products, potentially strengthening its position in the regenerative medicine market.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen401.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
Healios KK announced its development policy for HLCM051, prioritizing its use as a treatment for ARDS. The company plans to initiate a global Phase 3 study in early 2026, with patient enrollment starting in Japan and expanding to the United States. While discussions continue for the ischemic stroke treatment under the SAKIGAKE Designation System, the application will not proceed in a rolling submission format by early 2026. This development strategy is not expected to impact the company’s financial results for the fiscal year ending December 2025.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen401.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
Healios K.K. has released its financial results for the third quarter of fiscal year 2025. The announcement provides insights into the company’s current financial standing and strategic direction, which could impact its operations and market position in the regenerative medicine sector. Stakeholders should consider the potential implications of these results on future company performance.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen401.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.